Correlations between glucagon stimulated C-peptide levels and microvascular complications in type 2 diabetes patients

Diabetes and Metabolism Journal

Volumn 36, Issue 5, 2012, Pages 379-387

  Yoon, Hye Jin ^a   Cho, Youn Zoo ^a   Kim, Ji Young ^a   Kim, Byung Joon ^a   Park, Keun Young ^a   Koh, Gwan Pyo ^b   Lee, Dae Ho ^b   Lim, Dong Mee ^a  

^a Konyang University College of Medicine   (South Korea)

^b Jeju National University   (South Korea)

Author keywords

Basal C peptide; Diabetes mellitus; Glucagon stimulation test; Microvascular complications; Stimulated C peptide; Type 2

Indexed keywords

EID: 84870257305     PISSN: 22336079     EISSN: 22336087     Source Type: Journal    
DOI: 10.4093/dmj.2012.36.5.379     Document Type: Article

References (25)

1. Faber OK, Hagen C, Binder C, Markussen J, Naithani VK, Blix PM, Kuzuya H, Horwitz DL, Rubenstein AH, Rossing N. Kinetics of human connecting peptide in normal and diabetic subjects. J Clin Invest 1978;62:197-203.
2. Kuhl C, Faber OK, Hornnes P, Jensen SL. C-peptide metabolism and the liver. Diabetes 1978;27 Suppl 1:197-200.
3. Marx N, Walcher D. C-Peptide and atherogenesis: C-Peptide as a mediator of lesion development in patients with type 2 diabetes mellitus? Exp Diabetes Res 2008;2008:385108.
4. Forst T, Kunt T, Wilhelm B, Weber MM, Pfutzner A. Role of C-Peptide in the regulation of microvascular blood flow. Exp Diabetes Res 2008;2008:176245.
5. Sari R, Balci MK. Relationship between C peptide and chronic complications in type-2 diabetes mellitus. J Natl Med Assoc 2005;97:1113-8.
6. Chowta MN, Adhikari PM, Chowta NK, Shenoy AK, D'Souza S. Serum C peptide level and renal function in diabetes mellitus. Indian J Nephrol 2010;20:25-8.
7. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26:832-6.
8. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53: 250-64.
9. Scheen AJ, Castillo MJ, Lefebvre PJ. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes Metab 1996;22:397-406.
10. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-71.
11. Abdullah BB, Patil BS, Thaseen A. Significance of C-peptide in type 2 diabetics: a study in the North Karnataka population of India. Al Ameen J Med Sci 2010;3:65-78.
12. Koyama K, Chen G, Lee Y, Unger RH. Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Physiol 1997;273(4 Pt 1):E708-13.
13. Kim BY, Jung CH, Mok JO, Kang SK, Kim CH. Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients. Acta Diabetol 2012;49:9-15.
14. Garcia-Webb P, Bonser A, Welborn TA. Correlation between fasting serum C-peptide and B cell insulin secretory capacity in diabetes mellitus. Diabetologia 1982;22:296.
15. Gottsater A, Landin-Olsson M, Fernlund P, Gullberg B, Lernmark A, Sundkvist G. Pancreatic beta-cell function evaluated by intravenous glucose and glucagon stimulation: a comparison between insulin and C-peptide to measure insulin secretion.Scand J Clin Lab Invest 1992;52:631-9.
16. Jones AG, Besser RE, McDonald TJ, Shields BM, Hope SV, Bowman P, Oram RA, Knight BA, Hattersley AT. Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes. Diabet Med 2011;28:1034-8.
17. Faber OK, Binder C. C-peptide response to glucagon: a test for the residual beta-cell function in diabetes mellitus. Diabetes 1977;26:605-10.
18. Inukai T, Matsutomo R, Tayama K, Aso Y, Takemura Y. Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus. Exp Clin Endocrinol Diabetes 1999;107:40-5.
19. Shin SJ, Lee YJ, Hsaio PJ, Chen JH, Guh JY, Chen MT, Chen WC, Tsai JH. Relationships between beta-cell function and diabetic duration and albuminuria in type 2 diabetes mellitus. Pancreas 1997;14:192-8.
20. Toyry JP, Niskanen LK, Mantysaari MJ, Lansimies EA, Haffner SM, Miettinen HJ, Uusitupa MI. Do high proinsulin and C-peptide levels play a role in autonomic nervous dysfunction? Power spectral analysis in patients with non-insulin-dependent diabetes and nondiabetic subjects. Circulation 1997;96:1185-91.
21. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol 2000;37:125-9.
22. Klein R, Klein BE, Moss SE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVI. The relationship of C-peptide to the incidence and progression of diabetic retinopathy. Diabetes 1995;44:796-801.
23. Sjoberg S, Gunnarsson R, Gjotterberg M, Lefvert AK, Persson A, Ostman J. Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987;30:208-13.
24. Sima AA, Zhang W, Grunberger G. Type 1 diabetic neuropathy and C-peptide. Exp Diabesity Res 2004;5:65-77.
25. Kamiya H, Zhang W, Sima AA. The beneficial effects of C-Peptide on diabetic polyneuropathy. Rev Diabet Stud 2009;6:187-202.